AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AIFF · NASDAQ · Software - Application

Firefly Neuroscience

FDA-cleared EEG assessment systems and brain-function reports for clinicians and drug developers.

$1.08

After-hours close−0.01 (−0.92%)

At close$1.09(+0.93%)

Something off on this page? Send us feedback.

Profile

Firefly Neuroscience, Inc.AIFFInformation Technology

Provides FDA-cleared EEG and event-related-potential assessment systems that turn standardized recordings into clinician-facing brain-function reports, while serving pharmaceutical research partners. Revenue comes from equipment-linked subscriptions, assessments, sales, rentals, services, and projects through a single core platform concentrated primarily in North America.

Combines the FDA-cleared Evoke System and Brain Network Analytics platform to capture EEG and event-related-potential data, compare it with standardized reference data, and produce structured reports that complement clinical evaluation, treatment planning, and longitudinal management. Sales reach healthcare professionals in neurology, psychiatry, transcranial magnetic stimulation, and cognitive care, alongside pharmaceutical collaborators supporting neuroscience drug development.

Generates revenue through equipment-linked subscriptions, per-assessment fees, equipment sales and rentals, projects or clinical studies, and related services. The Firefly Products segment uses one core software platform and derives revenue primarily in North America. Commercialization depends on use within FDA-cleared claims, health-data and privacy compliance, database quality, cloud availability, and continued clinical-site and pharmaceutical-project activity.

Company facts

CEOGreg Lipschitz

ListedAug 13, 2024

ExchangeNASDAQ

HeadquartersKenmore, NY

CountryCanada

Employees17

CIK0000803578

ISINUS3179701012

Key statistics

Market cap$16.0M

EPS (ttm)−$0.6264

P/E (ttm)−1.72

ROE-90.2%

P/B1.52

P/S8.88

Dividend yield—

Beta1.21vs XLK −0.02

Year to date +22.5% · Average volume (30d) 117.1K

Analysts

No analyst consensus on record.

Earnings

EPS

Estimate—

Reported−$0.10

Revenue

Estimate—

Reported$514.0K

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	—	−$0.10	—	—	$514.0K	—	−0.83%
Jun 30, 2026Q1 FY26	—	−$0.13	—	—	$485.0K	—	+6.61%
May 12, 2026Q1 FY26	—	−$0.13	—	—	$412.0K	—	0.00%
Nov 12, 2025Q3 FY25	—	−$0.20	—	—	$388.0K	—	−8.05%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$43.0K	$299.0K	$388.0K	$412.0K	$485.0K	$514.0K
Gross profit	$43.0K	$274.0K	$146.0K	$182.0K	$221.0K	$253.0K
Operating income	−$2.1M	−$1.6M	−$2.7M	−$2.3M	−$2.0M	−$2.0M
Net income	−$12.9M	−$1.8M	−$2.6M	−$2.5M	−$2.0M	−$2.0M
Diluted EPS	−$1.74	−$0.14	−$0.20	−$0.20	−$0.13	−$0.10
Gross margin	100.0%	91.6%	37.6%	44.2%	45.6%	49.2%
Operating margin	-4,802.3%	-546.5%	-684.5%	-546.1%	-414.4%	-384.0%

Fiscal years (4-quarter sums)FY24 $2.0M · FY25 $1.1M

Balance sheet, Jun 30, 2026Cash & short-term investments $9.2M · Total debt $0 · Total assets $16.8M · Shareholders' equity $14.7M

Dividends

No dividends on record.

Ownership

Institutions 8.14%1.20M sharesInsiders 7.74%1.14M sharesOther 84.12%12.44M shares

Shares outstanding 14.79M · Float 13.38M · 90.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Windsor Private Capital LP · 10 percent owner	1.24M	8.36%	Form 4	Oct 22, 2025
Gregory Lipschitz · director, officer: Interim CEO	933.9K	6.31%	Form 4	Mar 13, 2026
Jane Street Group, LLC	180.2K	1.22%	13F	May 12, 2026
Schonfeld Strategic Advisors LLC	177.2K	1.20%	13F	May 15, 2026
BlackRock, Inc.	169.4K	1.14%	13F	May 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Oct 22, 2025	Windsor Private Capital LP	10 percent owner	−78,031	$2.07
Oct 21, 2025	Windsor Private Capital LP	10 percent owner	−19,222	$2.40
Oct 20, 2025	Windsor Private Capital LP	10 percent owner	−33,500	$2.46
Oct 17, 2025	Windsor Private Capital LP	10 percent owner	−45,036	$2.55
Oct 16, 2025	Windsor Private Capital LP	10 percent owner	−40,139	$2.65